Scope of the Study
Avian influenza refers to the infectious disease caused by the bird flu Type A viruses. These viruses occur naturally among wild aquatic birds worldwide and can infect domestic poultry and other bird and animal species. Humans can also get affected by the infection if the virus enters the eyes, nose, or mouth. The avian influenza vaccine market is expected to grow in the future due to the increasing prevalence of infection and the growing demand for poultry consumption. It widely finds its application in Duck, Chicken, Goose, and other birds.
The market study is being classified by Type (Inactivated Vaccines, Live Recombinant Vaccines and Combination Vaccines), by Application (Chicken, Duck & Goose and Others) and major geographies with country level break-up.
Boehringer Ingelheim Animal Health (France), QianYuanHao Biological Corporation Limited (China), Harbin Veterinary Research Institute (China), CEVA (France), Qingdao Yebio Biological Engineering Co., Ltd (China), Zoetis Inc. (United States), FATRO S.p.A. (Italy) and Merck Animal Health (United States) are some of the key players profiled in the study.
Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Avian Influenza Vaccines market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Avian Influenza Vaccines market by Type, Application and Region.
On the basis of geography, the market of Avian Influenza Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Awareness About the Avian Influenza Vaccines
- Growing Demand from Poultry Consumption
- Collaboration and Tie Up Of Leading Players
- Issues Regarding Vaccine Degradation at Room Temperature
- Increasing R&D Expenses for New Vaccines
- Rising Government Initiatives for Vaccines against Avian Influenza
- Lack of Awareness about the Disease among People who Maintain Poultry
Market Leaders and their expansionary development strategies
In July 2019, Ceva Santé Animale (“Ceva”) and IDT Biologika GmbH (“IDT”) announced that they have successfully completed the acquisition of IDT’s veterinary biopharmaceutical and R&D activities by Ceva.
In Sept 2019, Boehringer Ingelheim is developing one of the largest biotechnology production sites for veterinary vaccines in Europe, building on France’s pioneering expertise in veterinary public health (VPN)., and On 26 April 2018, Zoetis announced to expand animal vaccine research and manufacturing in Suzhou, China. The company begins the construction of state-of-the-art vaccine manufacturing and research and development facilities in Suzhou to support growth. Operations to focus on the development and manufacturing of vaccines for pigs, cattle and fish and companion animals tailored to the animal health needs of China.
Key Target AudienceInfluenza Vaccines Manufacturers, Influenza Vaccines Traders, End-Use Market Participants of Different Segments of Influenza Vaccines, Government and Research Organizations, R&D Institutions and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase